https://scholars.lib.ntu.edu.tw/handle/123456789/539754
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Liu C.W. | en_US |
dc.contributor.author | WEN-JEN LIN | en_US |
dc.date.accessioned | 2021-01-07T07:17:21Z | - |
dc.date.available | 2021-01-07T07:17:21Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1061186X | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84883235338&doi=10.3109%2f1061186X.2013.811511&partnerID=40&md5=2b1decb3c563549157afc3745f6fbb60 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/539754 | - |
dc.description.abstract | The aim of this study was to develop the heptapeptide-conjugated active targeting nanoparticles for delivery of doxorubicin and siRNA to epidermal growth factor receptor (EGFR) high-expressed breast cancer cells. The active targeting nanoparticles were prepared by using a synthesized poly(D,L-lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG) copolymer conjugated with a heptapeptide. The particle size of peptide-conjugated nanoparticles was less than 200 nm with narrow size distribution and the surface charge was negative. The uptake of peptide-conjugated nanoparticles was more efficient in EGFR high-expressed MDA-MB-468 cells than in EGFR low-expressed HepG2 cells by 3.9 folds due to peptide specific binding to EGF receptor followed by EGF receptor-mediated endocytosis. The nanoparticles were used to deliver doxorubicin and siRNA, and their in vitro release was faster in pH 4.0 (500 U lipase) than in pH 7.4. The IC50 of doxorubicin-loaded peptide-conjugated nanoparticles was lower than that of peptide-free nanoparticles by 2.3 folds in MDA-MB-468 cells. Similarly, the cellular growth inhibition of siRNA/DOTAP-loaded peptide-conjugated nanoparticles was 2.1 folds higher than that of peptide-free nanoparticles. In conclusion, the heptapeptide-conjugated PLGA-PEG nanoparticles provided active targeting potential to EGFR high-expressed MDA-MB-468 breast cancer cells, and a synergistic cytotoxicity effect was achieved by co-delivery of doxorubicin and siRNA/DOTAP-loaded peptide-conjugated nanoparticles. ? 2013 Informa UK Ltd. | - |
dc.relation.ispartof | Journal of Drug Targeting | - |
dc.subject | Cancer targeting; Nanoparticles; Peptide; PLGA-PEG; SiRNA | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | 1,2 dioleoyl 3 trimethylammoniopropane; copolymer; doxorubicin; epidermal growth factor receptor; heptapeptide; nanoparticle; poly(lactide co glycolide) pol(ethylene glycol) copolymer; small interfering RNA; unclassified drug; article; breast cancer; cancer inhibition; cell strain HepG2; chemosensitization; controlled study; drug conjugation; drug cytotoxicity; drug delivery system; drug potentiation; drug receptor binding; drug release; drug targeting; endocytosis; human; human cell; IC 50; in vitro study; particle size; pH; priority journal; protein expression; surface property; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Endocytosis; Female; Hep G2 Cells; Humans; Nanoparticles; Particle Size; Peptides; Polyethylene Glycols; Polyglactin 910; Receptor, Epidermal Growth Factor; RNA, Small Interfering | - |
dc.title | Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.3109/1061186X.2013.811511 | - |
dc.identifier.pmid | 23829387 | - |
dc.identifier.scopus | 2-s2.0-84883235338 | - |
dc.relation.pages | 776-786 | - |
dc.relation.journalvolume | 21 | - |
dc.relation.journalissue | 8 | - |
item.openairetype | journal article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Pharmacy | - |
crisitem.author.dept | School of Pharmacy | - |
crisitem.author.orcid | 0000-0001-9879-1071 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 藥學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。